SomaGenics, founded in Santa Cruz, CA, is a privately held biotech company focused on small RNA technologies. Their core mission is to advance RNA-based therapeutics and diagnostics, with a vision to revolutionize the treatment and detection of diseases at the molecular level. SomaGenics offers innovative RNAi-based therapeutics using their proprietary sshRNA molecules and provides high-sensitivity PCR technology for the detection of microRNAs and other small RNAs in both biofluids and total RNA inputs.

Notable figures associated with SomaGenics include leading scientists and biotech investors who have contributed to its growth and innovation. The company has achieved significant milestones, such as pioneering the development of sshRNA, which boasts superior potency and favorable pharmacokinetic properties without triggering undesirable immune responses. SomaGenics' advancements in RNA technology have had a substantial impact on the biotech industry, particularly in the fields of therapeutics and diagnostics.